Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;17(1 Suppl 1):3-10.

Background and Evaluation of Hypercoagulability

Robert G Gish, Fredric G Regenstein

Background and Evaluation of Hypercoagulability

Robert G Gish et al. Gastroenterol Hepatol (N Y). 2021 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

In the past 2 years, Dr Gish has received grants/research support from Gilead. He has performed as a consultant and/or advisor (in the last 2 years) to Abbott, AbbVie, Access Biologicals, Antios, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Forty-Seven Inc, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Salix, Shionogi, and Viking Therapeutics. He is currently active on the scientific or clinical advisory boards of Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, HepQuant, Intercept, and Janssen. He is a member of the Clinical Trials Alliance of Topography Health. He is the Chair of the Clinical Advisory Board of Prodigy. He is an advisory consultant for the diagnostic companies BioCollections, Fujifilm/Wako, and Quest. He is a member of the Data Safety Monitoring Board of Arrowhead. Dr Regenstein has no real or apparent conflicts of interest to report.

Figures

Figure 1.
Figure 1.
Endothelial damage: initiation of thrombin generation. FXI, factor XI.
Figure 2.
Figure 2.
Rotational thromboelastometry: clot formation in whole blood. Courtesy: R. Todd Stravitz, MD.
Figure 3.
Figure 3.
Viscoelastic measurement of clot formation in whole blood. ROTEM, rotational thromboelastometry; TEG, thromboelastography. Courtesy: R. Todd Stravitz, MD.
Figure 4.
Figure 4.
The parameters of a temogram using the terminology for TEG. R, measure of coagulation time from start to initial fibrin formation. Alpha angle, the angle between the midline and a line tangential to the developing “body” of the TEG trace. Represents clot kinetics of clot buildup and crosslinking. MA, maximum amplitude is the maximum width of the “body” of the TEG trace. Represents ultimate clot strength.
Figure 5.
Figure 5.
A comparison of the terminology used in ROTEM (A) and TEG (B). The depictions demonstrate clot initiation, propagation, stabilization, and lysis. Adapted from Whiting D and DiNardo JA. Am J Hematol. 2014;89(2):228-232.
See this image and copyright information in PMC

References

    1. Spaggiari M, Di Benedetto F, Masetti M et al. The impact of inherited thrombophilia on liver transplantation. Transplantation. 2009;87(7):1103–1104. - PubMed
    1. Abdel-Razik A, Mousa N, Elhelaly R, Tawfik A. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system. Eur J Gastroenterol Hepatol. 2015;27(5):585–592. - PubMed
    1. Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral anticoagulation in patients with liver disease. J Am Coll Cardiol. 2018;71(19):2162–2175. - PubMed
    1. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31(3):366–374. - PubMed
    1. Ponziani FR, Zocco MA, Garcovich M, D’Aversa F, Roccarina D, Gasbarrini A. What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective. World J Gastroenterol. 2012;18(36):5014–5020. - PMC - PubMed

LinkOut - more resources